A Phase II Study of the Combination of Avastin [bevacizumab] and Erlotinib in Patients with Unresectable Hepatocellular Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2014
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 09 Dec 2011 Actual patient number is 62 according to ClinicalTrials.gov.
- 09 Dec 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
- 09 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.